Xianli Wang

Dr. Xianli Wang

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2024 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
HYHaiyang Yao
Haiyang Yao
YWYilun Wu
Yilun Wu
YZYiming Zhong
Yiming Zhong
CHChenxuan Huang
Chenxuan Huang
ZGZimo Guo
Zimo Guo
XWXianli Wang
Xianli Wang

25 March 2025 in Translational Neurodegeneration
Verified
Journal Article
Open access
PDF file
WZWenchuan Zhang
Wenchuan Zhang
CHChenxuan Huang
Chenxuan Huang
HYHaiyang Yao
Haiyang Yao
SYShangzhi Yang
Shangzhi Yang
ZJZeyidan Jiapaer
Zeyidan Jiapaer
XWXianli Wang
Xianli Wang
Neurological disorders present considerable challenges in diagnosis and treatment due to their complex and diverse etiology. Retrotransposons are a type of mobile genetic element that are increasingly revealed to play a role in these diseases. This review provides a detailed overview of recent developments in the study of retrotransposons in neurodevelopment, neuroaging, and neurological diseases. Retrotransposons, including long interspersed nuclear elements-1, Alu, SINE-VNTR-Alu, and endogenous retrovirus, play important regulatory roles in the development and aging of the nervous system. They have also been implicated in the pathological processes of several neurological diseases, including Alzheimer's disease, X-linked dystonia-parkinsonism, amyotrophic lateral sclerosis, autism spectrum disorder, and schizophrenia. Retrotransposons provide a new perspective for understanding the molecular mechanisms underlying neurological diseases and provide insights into diagnostic and therapeutic strategies of these diseases.

14 January 2024 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
YZYiming Zhong
Yiming Zhong
GWGuangming Wang
Guangming Wang
SYShangzhi Yang
Shangzhi Yang
YZYang Zhang
Yang Zhang
XWXianli Wang
Xianli Wang

29 June 2023 in Journal of Molecular Medicine
Verified
Journal Article
Closed access
PDF file
HLHongyuan Liu
Hongyuan Liu
XWXianli Wang
Xianli Wang

15 April 2025 in Archives of Biochemistry and Biophysics
Verified
Journal Article
Closed access
YJYuxin Jing
Yuxin Jing
WZWei Zheng
Wei Zheng
ZZZhou Zhou
Zhou Zhou
HYHaiyang Yao
Haiyang Yao
WZWenchuan Zhang
Wenchuan Zhang
XWXianli Wang
Xianli Wang

3 October 2023 in Journal of Molecular Cell Biology
Verified
Journal Article
Open access
PDF file
HCHaixia Cheng
Haixia Cheng
LHLingyang Hua
Lingyang Hua
HTHailiang Tang
Hailiang Tang
ZBZhongyuan Bao
Zhongyuan Bao
XXXiupeng Xu
Xiupeng Xu
YGYe Gong
Ye Gong
Meningioma is one of the most common primary neoplasms in the central nervous system, but no specific molecularly targeted therapy has been approved for the clinical treatment of aggressive meningiomas. There is hence an urgent demand to decrypt the biological and molecular landscape of malignant meningioma. Here, through the in-silica prescreening and 10-year follow-up studies of 445 meningioma patients, we uncovered that CBX7 expression progressively decreases with malignancy grade and neoplasia stage in meningioma, and a high CBX7 expression level predicts a favorable prognosis in meningioma patients. CBX7 restoration significantly induces cell cycle arrest and inhibits meningioma cell proliferation. iTRAQ-based proteomics analysis indicated that CBX7 restoration triggers the metabolic shift from glycolysis to oxidative phosphorylation. The mechanistic study demonstrated that CBX7 promotes the proteasome-dependent degradation of c-MYC protein by transcriptionally inhibiting the expression of a c-MYC deubiquitinase, USP44, consequently attenuates c-MYC-mediated transactivation of LDHA transcripts, and further inhibits glycolysis and subsequent cell proliferation. More importantly, the functional role of CBX7 was further confirmed in subcutaneous and orthotopic meningioma xenograft mouse models and meningioma patients. Altogether, our results shed light on the critical role of CBX7 in meningioma malignancy progression and identify the CBX7/USP44/c-MYC/LDHA axis as a promising therapeutic target against meningioma progression.